Folgen
Seth C. Hopkins
Seth C. Hopkins
Sumitomo Pharma America
Bestätigte E-Mail-Adresse bei sunovion.com
Titel
Zitiert von
Zitiert von
Jahr
A non–D2-receptor-binding drug for the treatment of schizophrenia
KS Koblan, J Kent, SC Hopkins, JH Krystal, H Cheng, R Goldman, ...
New England Journal of Medicine 382 (16), 1497-1506, 2020
2962020
Dynamic measurement of myosin light-chain-domain tilt and twist in muscle contraction
JET Corrie, BD Brandmeier, RE Ferguson, DR Trentham, ...
Nature 400 (6743), 425-430, 1999
2541999
SEP-363856, a novel psychotropic agent with a unique, non-D2 receptor mechanism of action
N Dedic, PG Jones, SC Hopkins, R Lew, L Shao, JE Campbell, KL Spear, ...
Journal of Pharmacology and Experimental Therapeutics 371 (1), 1-14, 2019
1812019
Translational aspects of pharmacological research into anxiety disorders: the stress-induced hyperthermia (SIH) paradigm
CH Vinkers, MJV van Bogaert, M Klanker, SM Korte, R Oosting, ...
European journal of pharmacology 585 (2-3), 407-425, 2008
1292008
Inhibitors of kinesin activity from structure-based computer screening
SC Hopkins, RD Vale, ID Kuntz
Biochemistry 39 (10), 2805-2814, 2000
1272000
Fluorescence polarization transients from rhodamine isomers on the myosin regulatory light chain in skeletal muscle fibers
SC Hopkins, C Sabido-David, JET Corrie, M Irving, YE Goldman
Biophysical journal 74 (6), 3093-3110, 1998
1081998
Orientation changes of the myosin light chain domain during filament sliding in active and rigor muscle
SC Hopkins, C Sabido-David, UA Van Der Heide, RE Ferguson, ...
Journal of molecular biology 318 (5), 1275-1291, 2002
992002
Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: a translational imaging study with ketamine
M Kokkinou, EE Irvine, DR Bonsall, S Natesan, LA Wells, M Smith, ...
Molecular psychiatry 26 (6), 2562-2576, 2021
912021
Model-independent analysis of the orientation of fluorescent probes with restricted mobility in muscle fibers
RE Dale, SC Hopkins, UA an der Heide, T Marszałek, M Irving, ...
Biophysical journal 76 (3), 1606-1618, 1999
82*1999
Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study
CU Correll, KS Koblan, SC Hopkins, Y Li, H Dworak, R Goldman, ...
npj Schizophrenia 7 (1), 63, 2021
682021
Ulotaront: A TAAR1 Agonist for the Treatment of Schizophrenia
MLR Heffernan, LW Herman, S Brown, PG Jones, L Shao, MC Hewitt, ...
ACS medicinal chemistry letters 13 (1), 92-98, 2021
652021
Dasotraline for the treatment of attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled, proof-of-concept trial in adults
KS Koblan, SC Hopkins, K Sarma, F Jin, R Goldman, SH Kollins, A Loebel
Neuropsychopharmacology 40 (12), 2745-2752, 2015
602015
Orientation changes of fluorescent probes at five sites on the myosin regulatory light chain during contraction of single skeletal muscle fibres
C Sabido-David, SC Hopkins, LD Saraswat, S Lowey, YE Goldman, ...
Journal of molecular biology 279 (2), 387-402, 1998
561998
Dissociating anxiolytic and sedative effects of GABAAergic drugs using temperature and locomotor responses to acute stress
CH Vinkers, M Klanker, L Groenink, SM Korte, JM Cook, ML Van Linn, ...
Psychopharmacology 204, 299-311, 2009
542009
Electric field and conformational effects of cytochrome c and solvent on cytochrome c peroxidase studied by high-resolution fluorescence spectroscopy
H Anni, JM Vanderkooi, KA Sharp, T Yonetani, SC Hopkins, L Herenyi, ...
Biochemistry 33 (12), 3475-3486, 1994
401994
Effect of TAAR1/5-HT1A agonist SEP-363856 on REM sleep in humans
SC Hopkins, N Dedic, KS Koblan
Translational Psychiatry 11 (1), 228, 2021
382021
Structural, Kinetic, and Pharmacodynamic Mechanisms of d-Amino Acid Oxidase Inhibition by Small Molecules
SC Hopkins, MLR Heffernan, LD Saraswat, CA Bowen, L Melnick, ...
Journal of medicinal chemistry 56 (9), 3710-3724, 2013
382013
Benzo [d] isoxazol-3-ol DAAO inhibitors
QK Fang, S Hopkins, M Heffernan, M Chytil, P Wipf
US Patent 7,166,725, 2007
382007
Transformed PANSS factors intended to reduce pseudospecificity among symptom domains and enhance understanding of symptom change in antipsychotic-treated patients with …
SC Hopkins, A Ogirala, A Loebel, KS Koblan
Schizophrenia bulletin 44 (3), 593-602, 2018
352018
Pyrrole and pyrazole DAAO inhibitors
QK Fang, S Hopkins, M Heffernan, M Chytil
US Patent 7,488,747, 2009
352009
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20